Plasma levels of carnosine dipeptidase 1 decrease in prostate cancer patients with lymph node metastasis
(English)Manuscript (preprint) (Other academic)
There is a need for a better differentiation of aggressive tumors in prostate cancer to design a tailored treatment for each patient, preferably by a minimally invasive analysis of blood samples. In a previous study, we discovered a decrease of plasma levels of carnosine dipeptidase 1 (CNDP1) in association with aggressive prostate cancer. Now this relation has been investigated and characterized further by generating several new antibodies for extended analysis of CNDP1 in plasma. Multi-antibody sandwich assays were developed and applied to 1,214 samples from two Swedish cohorts that confirmed decreased levels of CNDP1 in plasma for patients with advanced disease. Therein, CNDP1 assays revealed superior differentiation for tumor N stages than clinical tPSA. Further investigations can now elucidate mechanisms behind decreasing levels of CNDP1 in plasma and primary in regards to lymph node metastasis.
Biochemistry and Molecular Biology
IdentifiersURN: urn:nbn:se:kth:diva-126386OAI: oai:DiVA.org:kth-126386DiVA: diva2:642224
FunderScience for Life Laboratory - a national resource center for high-throughput molecular bioscienceVinnovaKnut and Alice Wallenberg FoundationSwedish Research Council
QS 20132013-08-212013-08-212013-08-21Bibliographically approved